High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY.
Rhee J, et al. Among authors: cha y.
Breast Cancer Res Treat. 2011 Jan;125(1):107-14. doi: 10.1007/s10549-010-1200-9. Epub 2010 Oct 9.
Breast Cancer Res Treat. 2011.
PMID: 20936340